Cargando…
Sacituzumab govitecan: a new opportunity in the treatment of refractory metastatic triple-negative breast cancer
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AME Publishing Company
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9073799/ https://www.ncbi.nlm.nih.gov/pubmed/35530936 http://dx.doi.org/10.21037/atm-21-6999 |
| _version_ | 1784701366656040960 |
|---|---|
| author | Maltoni, Roberta Bravaccini, Sara |
| author_facet | Maltoni, Roberta Bravaccini, Sara |
| author_sort | Maltoni, Roberta |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9073799 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | AME Publishing Company |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-90737992022-05-07 Sacituzumab govitecan: a new opportunity in the treatment of refractory metastatic triple-negative breast cancer Maltoni, Roberta Bravaccini, Sara Ann Transl Med Editorial Commentary AME Publishing Company 2022-04 /pmc/articles/PMC9073799/ /pubmed/35530936 http://dx.doi.org/10.21037/atm-21-6999 Text en 2022 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
| spellingShingle | Editorial Commentary Maltoni, Roberta Bravaccini, Sara Sacituzumab govitecan: a new opportunity in the treatment of refractory metastatic triple-negative breast cancer |
| title | Sacituzumab govitecan: a new opportunity in the treatment of refractory metastatic triple-negative breast cancer |
| title_full | Sacituzumab govitecan: a new opportunity in the treatment of refractory metastatic triple-negative breast cancer |
| title_fullStr | Sacituzumab govitecan: a new opportunity in the treatment of refractory metastatic triple-negative breast cancer |
| title_full_unstemmed | Sacituzumab govitecan: a new opportunity in the treatment of refractory metastatic triple-negative breast cancer |
| title_short | Sacituzumab govitecan: a new opportunity in the treatment of refractory metastatic triple-negative breast cancer |
| title_sort | sacituzumab govitecan: a new opportunity in the treatment of refractory metastatic triple-negative breast cancer |
| topic | Editorial Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9073799/ https://www.ncbi.nlm.nih.gov/pubmed/35530936 http://dx.doi.org/10.21037/atm-21-6999 |
| work_keys_str_mv | AT maltoniroberta sacituzumabgovitecananewopportunityinthetreatmentofrefractorymetastatictriplenegativebreastcancer AT bravaccinisara sacituzumabgovitecananewopportunityinthetreatmentofrefractorymetastatictriplenegativebreastcancer |